Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: A preclinical model for human therapies

Molecular Therapy

Volumn 20, Issue 8, 2012, Pages 1501-1507

  Wang, Zejing ^a,b   Storb, Rainer ^a,b   Halbert, Christine L ^a   Banks, Glen B ^b   Butts, Tiffany M ^a   Finn, Eric E ^b   Allen, James M ^b   Miller, A Dusty ^a   Chamberlain, Jeffrey S ^b,c   Tapscott, Stephen J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DYSTROPHIN; MICRO DYSTROPHIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; PARVOVIRUS VECTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOG; DUCHENNE MUSCULAR DYSTROPHY; DYSTROPHIN GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MUSCLE BIOPSY; NONHUMAN; SKELETAL MUSCLE; THERAPY EFFECT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS NEUTRALIZATION;

ANIMALIA; CANIS FAMILIARIS; MIRIDAE;

EID: 84864558640     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.111     Document Type: Article

References (49)

1. Muntoni, F, Torelli, S and Ferlini, A (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2: 731-740.
2. Ervasti, JM (2006). Structure and function of the dystrophin-glycoprotein complex. In Winder, SJ (ed). Molecular Mechanisms of Muscular Dystrophies. Landes Bioscience: Georgetown, TX, pp 1-13.
3. Ahn, AH and Kunkel, LM (1993). The structural and functional diversity of dystrophin. Nat Genet 3: 283-291.
4. Wang, Z, Chamberlain, JS, Tapscott, SJ and Storb, R (2009). Gene therapy in large animal models of muscular dystrophy. ILAR J 50: 187-198.
5. Gregorevic, P, Blankinship, MJ, Allen, JM, Crawford, RW, Meuse, L, Miller, DG et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 10: 828-834.
6. Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, G et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alphasarcoglycan and associated proteins. Ann Neurol 66: 290-297.
7. Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.
8. Wang, Z, Tapscott, SJ, Chamberlain, JS and Storb, R (2011). Immunity and AAVMediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Front Microbiol 2: 201.
9. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ, et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response erratum appears in Nat Med. 2006 May;12(5):592. Nat Med 12: 342-347.
10. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422.
11. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 2077-2086.
12. Mendell, JR, Rodino-Klapac, LR, Rosales, XQ, Coley, BD, Galloway, G, Lewis, S et al. (2010). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638.
13. Hoffman, EP, Bronson, A, Levin, AA, Takeda, S, Yokota, T, Baudy, AR et al. (2011). Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through. Am J Pathol 179: 12-22.
14. Aartsma-Rus, A, den Dunnen, JT and van Ommen, GJ (2010). New insights in genederived therapy: the example of Duchenne muscular dystrophy. Ann N Y Acad Sci 1214: 199-212.
15. Vilquin, JT, Catelain, C and Vauchez, K (2011). Cell therapy for muscular dystrophies: advances and challenges. Curr Opin Organ Transplant 16: 640-649.
16. Negroni, E, Vallese, D, Vilquin, JT, Butler-Browne, G, Mouly, V and Trollet, C (2011). Current advances in cell therapy strategies for muscular dystrophies. Expert Opin Biol Ther 11: 157-176.
17. Palmieri, B, Tremblay, JP and Daniele, L (2010). Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant 14: 813-819.
18. Wang, Z, Allen, JM, Riddell, SR, Gregorevic, P, Storb, R, Tapscott, SJ et al. (2007). Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 18: 18-26.
19. Yue, Y, Ghosh, A, Long, C, Bostick, B, Smith, BF, Kornegay, JN et al. (2008). A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs. Mol Ther 16: 1944-1952.
20. Yuasa, K, Yoshimura, M, Urasawa, N, Ohshima, S, Howell, JM, Nakamura, A et al. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. Gene Ther 14: 1249-1260.
21. Ohshima, S, Shin, JH, Yuasa, K, Nishiyama, A, Kira, J, Okada, T et al. (2009). Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 17: 73-80.
22. Gregorevic, P, Schultz, BR, Allen, JM, Halldorson, JB, Blankinship, MJ, Meznarich, NA et al. (2009). Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Mol Ther 17: 1427-1433.
23. Wang, Z, Storb, R, Lee, D, Kushmerick, MJ, Chu, B, Berger, C et al. (2010). Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther 18: 617-624.
24. Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15: 1160-1166.
25. Lapidos, KA, Kakkar, R and McNally, EM (2004). The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 94: 1023-1031.
26. Ervasti, JM and Campbell, KP (1991). Membrane organization of the dystrophinglycoprotein complex. Cell 66: 1121-1131.
27. Tidball, JG (1991). Force transmission across muscle cell membranes. J Biomech 24 (Suppl. 1): 43-52.
28. Tidball, JG and Law, DJ (1991). Dystrophin is required for normal thin filamentmembrane associations at myotendinous junctions. Am J Pathol 138: 17-21.
29. Banks, GB, Judge, LM, Allen, JM and Chamberlain, JS (2010). The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 6: e1000958.
30. Herson, S, Hentati, F, Rigolet, A, Romero, NB, Behin, A, Leturcq, F, et al. (2011). A phase I dose-escalating study of AAV1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Mol Ther 19 (Suppl. 1): S20-S21.
31. Bowles, DE, McPhee, SW, Li, C, Gray, SJ, Samulski, JJ, Camp, AS et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20: 443-455.
32. Kornegay, JN, Li, J, Bogan, JR, Bogan, DJ, Chen, C, Zheng, H et al. (2010). Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 18: 1501-1508.
33. Halbert, CL, Madtes, DK, Vaughan, AE, Wang, Z, Storb, R, Tapscott, SJ et al. (2010). Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vectormediated gene transfer to the lungs. Mol Ther 18: 1165-1172.
34. Koo, T, Okada, T, Athanasopoulos, T, Foster, H, Takeda, S and Dickson, G (2011). Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog. J Gene Med 13: 497-506.
35. Shin, JH, Yue, Y, Smith, B and Duan, D (2012). Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs. Hum Gene Ther 23: 287-289.
36. Rapti, K, Louis-Jeune, V, Kohlbrenner, E, Ishikawa, K, Ladage, D, Zolotukhin, S et al. (2012). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther 20: 73-83.
37. Arnett, AL, Garikipati, D, Wang, Z, Tapscott, S and Chamberlain, JS (2011). Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Front Microbiol 2: 220.
38. Storb, R, Yu, C, Wagner, JL, Deeg, HJ, Nash, RA, Kiem, HP et al. (1997). Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89: 3048-3054.
39. Yu, C, Seidel, K, Nash, RA, Deeg, HJ, Sandmaier, BM, Barsoukov, A et al. (1998). Synergism between mycophenolate mofetil and cyclosporine in preventing graftversus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood 91: 2581-2587.
40. Storb, R, Kolb, HJ, Graham, TC, Kolb, H, Weiden, PL and Thomas, ED (1973). Treatment of established graft-versus-host disease in dogs by antithymocyte serum or prednisone. Blood 42: 601-609.
41. Storb, R, Floersheim, GL, Weiden, PL, Graham, TC, Kolb, HJ, Lerner, KG et al. (1974). Effect of prior blood transfusions on marrow grafts: abrogation of sensitization by procarbazine and antithymocyte serum. J Immunol 112: 1508-1516.
42. Storb, R, Gluckman, E, Thomas, ED, Buckner, CD, Clift, RA, Fefer, A et al. (1974). Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 44: 56-75.
43. Storb, R, Etzioni, R, Anasetti, C, Appelbaum, FR, Buckner, CD, Bensinger, W et al. (1994). Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 84: 941-949.
44. Kahl, C, Leisenring, W, Deeg, HJ, Chauncey, TR, Flowers, ME, Martin, PJ et al. (2005). Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. Br J Haematol 130: 747-751.
45. Dell'Agnola, C, Wang, Z, Storb, R, Tapscott, SJ, Kuhr, CS, Hauschka, SD et al. (2004). Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood 104: 4311-4318.
46. Blankinship, MJ, Gregorevic, P, Allen, JM, Harper, SQ, Harper, H, Halbert, CL et al. (2004). Efficient transduction of skeletal muscle using vectors based on adenoassociated virus serotype 6. Mol Ther 10: 671-678.
47. Rafael, JA, Cox, GA, Corrado, K, Jung, D, Campbell, KP and Chamberlain, JS (1996). Forced expression of dystrophin deletion constructs reveals structure-function correlations. J Cell Biol 134: 93-102.
48. Banks, GB, Combs, AC, Chamberlain, JR and Chamberlain, JS (2008). Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum Mol Genet 17: 3975-3986.
49. Halbert, CL, Miller, AD, McNamara, S, Emerson, J, Gibson, RL, Ramsey, B et al. (2006). Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440-447.